Purpose of review: Immunomonitoring technologies are not only fast changing, but also have already revolutionized the way we look at treatments, diagnosis, and prognosis of a given disease. The purpose of the review is to provide a recent update on the use or possible use of array-based data in immunomonitoring of HIV patients.
Recent findings: Since the inception of gene arrays, there has been a rapid surge in the development of a variety of array-based technologies, which comprise of gene and protein expression platforms. These have been instrumental in studying various immunological and genomic aspects of HIV disease at the subcellular level.
Summary: Gene and protein array technologies are ideal for a high-throughput multiplexing of large datasets in determining the difference between diseased and nondiseased and pretreatment and posttreatment stages of HIV patients. Therefore, these technologies have the potential to revolutionize HIV immunomonitoring, treatment, diagnosis and prognosis. Although the array-based technologies have not yet replaced conventional immunomonitoring, the data coming out from high-throughput transcriptomic and proteomic studies and its global integration will lead to developing new generation of candidates and tools for immunomonitoring of HIV disease.
aRetroviral Genetics Division, Center for Virus Research, Westmead Millennium Institute, Westmead Hospital, The University of Sydney, Westmead, Sydney, New South Wales
bSchool of Biomedical Sciences and Pharmacy, Faculty of Health, The University of Newcastle, Callaghan, New South Wales, Australia
Correspondence to Nitin K. Saksena, Retroviral Genetics Division, Centre for Virus Research, Westmead Millennium Institute, Westmead Hospital, The University of Sydney, Darcy Road, Westmead, Sydney, NSW 2145, Australia. Tel: +612 9845 9119; fax: +612 9845 9103; e-mail: email@example.com